Published: 11 August 2022
Author(s): Martina Zappa, Paolo Verdecchia, Antonio Spanevello, Fabio Angeli
Issue: October 2022
Section: Clinical Insights

The Omicron BA.5 variant currently accounts for the majority of cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (https://covid.cdc.gov/covid-data-tracker/#variant-proportions). This subvariant evolved from the Omicron lineage and became more contagious. Furthermore, data suggest that Omicron sublineages may evade polyclonal neutralizing antibody responses elicited by primary vaccine series [1,2]. Of note, development of antibodies to SARS-CoV-2 largely revolves around the viral spike (S) glycoprotein [3], which mediates host cell entry by binding to a cell surface receptor, angiotensin-converting enzyme 2 (ACE2, Fig. 1) [4].

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness